<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782808</url>
  </required_header>
  <id_info>
    <org_study_id>SEARCH 011</org_study_id>
    <nct_id>NCT00782808</nct_id>
  </id_info>
  <brief_title>Peripheral Reservoir of HIV DNA in Monocytes Pivotal to Cognition in HIV</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>South East Asia Research Collaboration with Hawaii</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>South East Asia Research Collaboration with Hawaii</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sixty HIV participants will be enrolled and stratified by PBMC HIV DNA levels, either high&#xD;
      (greater than or equal to 5000 copies/106 cells) or low (less than 5000 copies/106 cells).&#xD;
      Individuals will be enrolled into each group until filled. Screening PBMC HIV DNA levels will&#xD;
      be performed at SEARCH in real-time with less than one-week turn around time. All individuals&#xD;
      will intend to initiate ARV due to meeting MOPH guidelines for such. The protocol team will&#xD;
      work with the primary care physician to facilitate initiation of standard ARV care; however,&#xD;
      initiation of ARV is not a requirement of the study and ARV will not be provided by the&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the long-term relationship between cognition and HIV DNA in circulating PBMCs and monocytes (CD14+ PBMCs) among patients initiating HAART for the first time</measure>
    <time_frame>After March 30, 2016</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1 HIV DNA will be stratified by high</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>2 HIV DNA will be stratified by low</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected individuals meeting MOPH criteria to initiate HAART and planning to initiate&#xD;
        HAART within a month of screening. Consequently, all participants will have plasma CD4&#xD;
        counts at less than 250 cells.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-infected individuals meeting MOPH criteria to initiate HAART and planning to&#xD;
             initiate HAART within a month of screening.&#xD;
&#xD;
          -  Consequently, all participants will have plasma CD4 counts at less than 250 cells.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Head injury with loss of consciousness greater than 1 hour or cognitive sequela&#xD;
&#xD;
          -  Current/past illicit drug use or positive drug screen for methamphetamines,&#xD;
             amphetamines, or cocaine at screening or entry.&#xD;
&#xD;
          -  Any of the following laboratory abnormalities:&#xD;
&#xD;
               -  PT/PTT &gt; the upper limit of normal (ULN) or INR &gt; 1.1&#xD;
&#xD;
               -  Hemoglobin &lt; 9.0 mg/dL&#xD;
&#xD;
               -  ALT &gt; 5x ULN&#xD;
&#xD;
               -  serum creatinine &gt; 2x ULN or creatinine clearance &lt; 30 cc per min by&#xD;
                  Cockroft-Gault formula&#xD;
&#xD;
          -  Acute illness within 30 days prior, persistent and active AIDS-defining OI of any&#xD;
             organ system or autoimmune disease.&#xD;
&#xD;
          -  Current or recent fevers or meningeal signs suggestive of CNS opportunistic infection&#xD;
&#xD;
          -  CNS opportunistic infection, past or present (Patients diagnosed with opportunistic&#xD;
             infection after CSF examination will be excluded from further analysis. In such a&#xD;
             situation, an additional patient will be enrolled)&#xD;
&#xD;
          -  History of pre-existing neurologic disease to include stroke, multiple sclerosis or&#xD;
             psychiatric illness including schizophrenia, bipolar disorder, anxiety disorder, panic&#xD;
             attacks, major depression, or post traumatic stress disorder. Patients with past&#xD;
             depression that is controlled and patients with or minor depressive symptoms will be&#xD;
             allowed to enroll.&#xD;
&#xD;
          -  Known learning disability including dyslexia or unable to read or write basic Thai&#xD;
&#xD;
          -  Positive Hepatitis C serology (Hepatitis C Ab)&#xD;
&#xD;
          -  Confusion or other signs and symptoms of metabolic encephalopathy or delirium&#xD;
&#xD;
          -  Other conditions that could explain neurocognitive decline in the opinion of the&#xD;
             investigator such as hypothyroidism, vitamin B12 deficiency or neurosyphilis&#xD;
&#xD;
          -  Pregnancy or metal objects that would preclude MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor Valcour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hawii</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SEARCH Thailand</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.searchthailand.org</url>
    <description>South East Asia Research Collaboration with Hawaii</description>
  </link>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>October 29, 2008</study_first_submitted>
  <study_first_submitted_qc>October 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>September 25, 2014</last_update_submitted>
  <last_update_submitted_qc>September 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South East Asia Research Collaboration with Hawaii</investigator_affiliation>
    <investigator_full_name>Assoc.Prof.Jintanat Ananworanich, M.D.</investigator_full_name>
    <investigator_title>Assoc.Prof</investigator_title>
  </responsible_party>
  <keyword>HIV DNA in Monocytes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

